Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost
Ionis Collaborating On Development
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
You may also be interested in...
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.